The nonpeptide glucagon-like peptide-1 receptor agonist orforglipron as a once-daily oral therapy is associated with clinically significant weight reduction.
Multiple members of The Obesity Society (TOS) unveiled new research about several anti-obesity medications in development at this year's annual meeting of the American Diabetes Association (ADA) held June 23–26.
New drugs line up to challenge Ozempic, Wegovy for weight loss medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Compared to orforglipron, Novo Nordisk’s Ozempic and Wegovy recently approved for weight loss are given as once-weekly injections; and Lilly’s diabetes drug Mounjaro, which also helps substantial weight loss, is an injectable medicine.